Aprinoia Therapeutics Inc.

Founded in 2015 by Ming-Kuei Jang and based in Grand Cayman, Cayman Islands, Aprinoia Therapeutics Inc. operates as a drug developer for neurodegenerative diseases, focusing on the research and development of new drugs for neurodegenerative diseases. In December 2021, Aprinoia Therapeutics Inc. raised USD 40 million in Series C funding led by Yantai Dongcheng Pharmaceutical Group Co.

, Ltd. , including IMM Investment, Harvest Capital, KTB Network, and TaiAn Technologies Corporation. As of 2024, the company is led by its CEO, Mark S. Shearman.

The company also has offices in the US, Hong Kong, China, and Japan. The company focuses on neurodegenerative diseases, which include disorders such as Alzheimer's disease, Parkinson's disease, and other tauopathies. The product pipeline includes [18F]-APN-1607 Florzolotau (18F), αSyn PET Tracer, APNmAb005, Tau Degrader, and αSyn Degrader. The firm’s pipeline comprises several diagnostic and therapeutic programs.

On the diagnostic front, the company is advancing imaging agents designed to improve the early detection and monitoring of neurodegenerative diseases. These agents enable accurate diagnosis and tracking of disease progression, guiding patient management and treatment decisions. In terms of therapeutics, Aprinoia is developing treatments aimed at halting or slowing disease progression. Their therapeutic candidates target pathological proteins, aiming to modify the underlying disease mechanisms rather than just alleviating symptoms.

The company also collaborates with academic institutions, healthcare providers, and industry partners to accelerate the translation of their research into clinical practice.